Stangel M - Search Results

1

Anti-leucine rich glioma inactivated 1 protein and anti-N-methyl-D-aspartate receptor encephalitis show distinct patterns of brain glucose metabolism in 18F-fluoro-2-deoxy-d-glucose positron emission tomography.

Wegner F, Wilke F, Raab P, Tayeb SB, Boeck AL, Haense C, Trebst C, Voss E, Schrader C, Logemann F, Ahrens J, Leffler A, Rodriguez-Raecke R, Dengler R, Geworski L, Bengel FM, Berding G, Stangel M, Nabavi E. Wegner F, et al. Among authors: stangel m. BMC Neurol. 2014 Jun 20;14:136. doi: 10.1186/1471-2377-14-136. BMC Neurol. 2014. PMID: 24950993 Free PMC article.

2

[Chemokine--possible new options for the treatment of multiple sclerosis].

Trebst C, Ransohoff RM, Windhagen A, Stangel M. Trebst C, et al. Among authors: stangel m. Nervenarzt. 2003 Oct;74(10):850-7. doi: 10.1007/s00115-003-1571-9. Nervenarzt. 2003. PMID: 14551688 Review. German.

3

Interferon-beta up-regulates the expression of co-stimulatory molecules CD80, CD86 and CD40 on monocytes: significance for treatment of multiple sclerosis.

Marckmann S, Wiesemann E, Hilse R, Trebst C, Stangel M, Windhagen A. Marckmann S, et al. Among authors: stangel m. Clin Exp Immunol. 2004 Dec;138(3):499-506. doi: 10.1111/j.1365-2249.2004.02624.x. Clin Exp Immunol. 2004. PMID: 15544628 Free PMC article.

4

[Cannabinoids in multiple sclerosis -- therapeutically reasonable?].

Trebst C, Stangel M. Trebst C, et al. Among authors: stangel m. Fortschr Neurol Psychiatr. 2005 Aug;73(8):463-9. doi: 10.1055/s-2004-830119. Fortschr Neurol Psychiatr. 2005. PMID: 16052440 Review. German.

5

[Concepts of lesion development in multiple sclerosis. Current approaches and clinical-therapeutic implications ].

Trebst C, Wiendl H, Stangel M. Trebst C, et al. Among authors: stangel m. Nervenarzt. 2006 Feb;77(2):158, 160-2, 164. doi: 10.1007/s00115-005-1994-6. Nervenarzt. 2006. PMID: 16160810 Review. German.

6

Promotion of remyelination by immunoglobulins: implications for the treatment of multiple sclerosis.

Trebst C, Stangel M. Trebst C, et al. Among authors: stangel m. Curr Pharm Des. 2006;12(2):241-9. doi: 10.2174/138161206775193118. Curr Pharm Des. 2006. PMID: 16454740 Review.

7

Remyelination strategies: new advancements toward a regenerative treatment in multiple sclerosis.

Stangel M, Trebst C. Stangel M, et al. Curr Neurol Neurosci Rep. 2006 May;6(3):229-35. doi: 10.1007/s11910-006-0010-2. Curr Neurol Neurosci Rep. 2006. PMID: 16635432 Review.

8

Expression of chemokine receptors on peripheral blood mononuclear cells of patients with immune-mediated neuropathies treated with intravenous immunoglobulins.

Trebst C, Brunhorn K, Lindner M, Windhagen A, Stangel M. Trebst C, et al. Among authors: stangel m. Eur J Neurol. 2006 Dec;13(12):1359-63. doi: 10.1111/j.1468-1331.2006.01521.x. Eur J Neurol. 2006. PMID: 17116220

9

Lack of interferon-beta leads to accelerated remyelination in a toxic model of central nervous system demyelination.

Trebst C, Heine S, Lienenklaus S, Lindner M, Baumgärtner W, Weiss S, Stangel M. Trebst C, et al. Among authors: stangel m. Acta Neuropathol. 2007 Dec;114(6):587-96. doi: 10.1007/s00401-007-0300-z. Epub 2007 Oct 17. Acta Neuropathol. 2007. PMID: 17940777

10

Effects of interferon-beta on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-beta treatment in patients with multiple sclerosis.

Wiesemann E, Deb M, Trebst C, Hemmer B, Stangel M, Windhagen A. Wiesemann E, et al. Among authors: stangel m. Mult Scler. 2008 Mar;14(2):166-76. doi: 10.1177/1352458507081342. Epub 2007 Oct 17. Mult Scler. 2008. PMID: 17942524 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

365 results

Search Page

Filters